Outsourcing Pharma

MARCH 18, 2024

The curtains have risen on DCAT 2024 in the vibran heart of New York City, and leading pharmaceutical companies from around the world have converged for a week of innovation, collaboration, and strategic dialogue.

Pharmaceutical Companies 90

Pharmaceutical Companies Pharmaceutical Companies 90

STAT

OCTOBER 21, 2024

WASHINGTON — Most executives at pharmaceutical companies haven’t directly donated to political candidates over the final stretch of the 2024 campaign. But those who have largely gave to Democrats. 

Pharmaceutical Companies 145

Pharmaceutical Companies Pharmaceutical Companies 145

STAT

OCTOBER 24, 2023

Following two decades of sharp increases for consumers, the companies vowed to cut insulin prices for some insulins by at least 70%, meaning many people could see their insulin costs capped at $35 a month in the near future. Sanofi and NovoNordisk will lower their prices as of January 2024; Lilly reduced it to $35 per month in March 2023.)

Pharmaceutical Companies 137

Pharmaceutical Companies Pharmaceutical Companies 137

STAT

APRIL 30, 2024

Eli Lilly raised its full-year guidance on Tuesday while it reported strong first-quarter sales of Zepbound, even as the pharmaceutical company struggles to make enough of the obesity drug to meet the enormous demand. Lilly increased its adjusted earnings guidance for 2024 to a range of $13.50 per share, beating the $2.39

Pharmaceutical Companies 134

Pharmaceutical Companies Pharmaceutical Companies 134

STAT

APRIL 22, 2025

Four months ago, a small pharmaceuticals company bought a medicine used to combat a rare growth disorder in children and quickly raised the list price by 150%. But the company, Eton Pharmaceuticals, argues there is no other way to keep its treatment on the market and make a profit.

Pharmaceutical Companies 114

Pharmaceutical Companies Pharmaceutical Companies 114

STAT

MARCH 18, 2024

The biggest enticement that large pharmacy benefit managers offer to the employers that hire them is drug rebates — a steady stream of money sent back to their clients, a tangible symbol of the discounts that PBMs are able to wrangle out of pharmaceutical companies. Continue to STAT+ to read the full story…

Documentation 145

Documentation Pharmaceutical Companies Pharmaceutical Companies Insurance 145

STAT

OCTOBER 17, 2024

As Election Day 2024 gets closer, STAT’s First Opinion asked executives from leading biotech and pharmaceutical companies to reflect on how their industry is being portrayed in the presidential campaign — and what their hopes are for a new presidential administration. You

Pharmaceutical Companies 136

Pharmaceutical Companies Pharmaceutical Companies FDA 136

STAT

OCTOBER 18, 2024

As Election Day 2024 gets closer, STAT’s First Opinion asked executives from leading biotech and pharmaceutical companies to reflect on how their industry is being portrayed in the presidential campaign — and what their hopes are for a new presidential administration. You

Pharmaceutical Companies 109

Pharmaceutical Companies Pharmaceutical Companies 109

STAT

MAY 22, 2024

A 2024 analysis of drugs included in this program showed they had 23% shorter clinical development timelines than those that were not part of the program, with no negative effects on their safety profiles.

Pharmaceutical Companies 122

Pharmaceutical Companies Pharmaceutical Companies 122

pharmaphorum

JUNE 12, 2025

Skip to main content Thursday 12 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Health and Personal Care Stores 59

Health and Personal Care Stores Pharmaceutical Companies Pharmaceutical Companies Insurance Coverage 59

Pharmafile

MARCH 17, 2023

French pharmaceutical company Sanofi has announced that it will cut the list price of its Lantus (insulin glargine injection) 100 units/ml by 78%, beginning January 2024. read more

Pharmaceutical Companies 59

Pharmaceutical Companies Pharmaceutical Companies Insurance 59

European Pharmaceutical Review

NOVEMBER 25, 2024

percent between 2024 and 2032. An increasing trend of outsourcing boosts growth of the market as pharmaceutical companies are utilising advanced testing capabilities and optimising their drug development processes. percent market share between 2024 and 2032, based on the forecast by Straits Research. billion by 2032.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Compounding 52

European Pharmaceutical Review

MARCH 27, 2025

As scientific and pharmaceutical companies grapple to secure the worlds best talent, the science and immigration sectors are aware that the UKs ability to attract global talent in science and technology is constantly under question. Summary of visa costs analysis 2024. How do the UKs immigration costs compare? References 1.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Labelling 52

The Guardian - Pharmaceutical Industry

APRIL 11, 2024

pay boost Shareholders at AstraZeneca are in line for a 7% increase in dividends this year as the pharmaceutical company attempts to garner support for a pay deal worth up to £19m for its boss, Pascal Soriot. AstraZeneca said it intended to increase the annual dividend for 2024 by $0.20

Pharmaceutical Companies 91

Pharmaceutical Companies Pharmaceutical Companies 91

InCrowd

APRIL 30, 2024

ASCO 2024, a pivotal conference for unveiling the latest advancements in cancer care, is just around the corner and oncologists are ready for it. Attendance Outlook: An impressive 72% of oncologists, whether attending in-person or virtually, are gearing up for ASCO 2024, underscoring the event’s importance in the oncology community.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies 52

European Pharmaceutical Review

NOVEMBER 1, 2024

The worldwide pharmaceutical container packaging market is expected to rise in revenue from $104.12 percent between 2024 and 2033. As pharmaceutical companies are making investments in sustainable packaging this is also driving demand in this market, based on analysis of the study’s findings.

Packaging 52

Packaging Pharmaceutical Companies Pharmaceutical Companies Dosage 52

European Pharmaceutical Review

AUGUST 3, 2023

EPC’s new Cannabis flower monograph The new monograph Cannabis flower (Cannabis flower, monograph 3028) will be available next year in January 2024 with publication of the supplement 11.5. The monograph will enter into force several months later, in July 2024. 1 July 2024).

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies Compounding 98

The Guardian - Pharmaceutical Industry

NOVEMBER 12, 2024

Britain’s biggest pharmaceutical company raises 2024 profit forecast and announces $3.5bn US investment Business live – latest updates AstraZeneca has said the drugmaker is taking investigations by Chinese authorities into its business in the country “very seriously” and will “fully cooperate” with them. Continue reading.

Pharmaceutical Companies 66

Pharmaceutical Companies Pharmaceutical Companies 66

STAT

JULY 10, 2024

… Biopharma layoffs have been higher over the past couple of years than during the industry’s boom times amid the Covid-19 pandemic, and job cuts this year have mainly hit larger pharmaceutical companies to a greater degree than in the past , according to STAT.

Pharmaceutical Companies 115

Pharmaceutical Companies Pharmaceutical Companies 115

Viseven

AUGUST 1, 2024

Because of these changes, pharmaceutical companies are rethinking how they do business. Main Advantages of CRM in the Pharma Industry Current market research shows steady growth in the global pharmaceutical CRM market, confirming the increasing adoption of the solution. each year from 2024 to 2033.

Communication 52

Communication Pharmaceutical Companies Pharmaceutical Companies 52

European Pharmaceutical Review

JUNE 10, 2024

Radioligand therapy developments in 2023 and 2024 Other companies making progress producing radioligand therapies include Novartis. In January 2024, the pharmaceutical company obtained manufacturing authorisation for its largest radioligand therapy facility. billion.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies 98

European Pharmaceutical Review

JUNE 26, 2024

This is in addition to the company’s current workforce in the region, which totals nearly 2,500 employees, the firm stated. They added that in 2024, it anticipates increasing its actual production investments. This is compared to the company’s $3.9 (DKK This is compared to the company’s $3.9 (DKK

Pharmaceutical Companies 104

Pharmaceutical Companies Pharmaceutical Companies 104

European Pharmaceutical Review

JUNE 7, 2024

Pharmaceutical companies ask themselves this question before embracing the latest technologies because every innovation comes with both opportunities and risks. European approach In March 2024, the European Parliament adopted the European AI Act, which is expected to enter into force in May or June 2024. Friend or foe?

Health and Personal Care Stores 113

Health and Personal Care Stores Pharmaceutical Companies Pharmaceutical Companies 113

Fierce Pharma

MARCH 28, 2024

[Yangzhou, China - March 26, 2024] - Aurisco Pharmaceutical, a leading global pharmaceutical company, is excited to announce the completion of its investment in cGMP peptide manufacturing capacity | Aurisco Pharmaceutical Launches State-of-the-Art Manufacturing Facility for GLP-1 Peptides

Pharmaceutical Companies 57

Pharmaceutical Companies Pharmaceutical Companies 57

Hospital Pharmacy Europe

NOVEMBER 9, 2023

It also allows pharmaceutical companies to monitor product information and keep it constantly updated, as well as offering healthcare professionals and patients greater accessibility. Pharmaceutical companies participating in the pilot create and submit the ePI via the PLM Portal as part of their regulatory application.

Adverse Reactions 97

Adverse Reactions Pharmaceutical Companies Pharmaceutical Companies Hospitals 97

European Pharmaceutical Review

NOVEMBER 13, 2023

The pharmaceutical company also highlighted that the decision was additionally supported by data from a subpopulation of adult patients with moderate to severe anaemia from the SIMPLIFY-1 Phase III trial. GSK shared that a decision on marketing authorisation for momelotinib in the EU is expected by early 2024.

Adverse Reactions 109

Adverse Reactions Pharmaceutical Companies Pharmaceutical Companies 109

The Guardian - Pharmaceutical Industry

MAY 2, 2024

Novo Nordisk, which is now Europe’s most valuable company, also reports strong sales of diabetes drug Ozempic Strong sales of diabetes and weight loss drugs Ozempic and Wegovy have prompted the Danish pharmaceutical company Novo Nordisk to raise its 2024 profit forecast to up to £15.3bn, with supply shortages starting to ease.

Pharmaceutical Companies 64

Pharmaceutical Companies Pharmaceutical Companies 64

PharmExec

APRIL 29, 2024

A Frost & Sullivan industry-wide survey reveals which insights most pharmaceutical companies have mastered and which are still painful or impossible to extract and details the complexity of the process, the confidence companies have in their findings, and more.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies 52

European Pharmaceutical Review

OCTOBER 26, 2023

Upon MHRA approval, the company plans to initiate a Phase IIa clinical trial to evaluate the multi ascending dose, safety and tolerability of PK051,” stated Dr Bob Smith, Clinical Director at PharmaKure. The first patient is expected to be dosed in early 2024, with clinical data emerging within 12 months of first dose.”

Pharmaceutical Companies 105

Pharmaceutical Companies Pharmaceutical Companies 105

European Pharmaceutical Review

SEPTEMBER 21, 2023

The new administration method will be available in the UK for tralokinumab patients from early 2024. Atopic dermatitis This chronic, inflammatory skin disease is characterised by symptoms such as intense itch and eczematous lesions.

Pharmaceutical Companies 105

Pharmaceutical Companies Pharmaceutical Companies Immunization 105

The Checkup by Singlecare

APRIL 15, 2025

In the case of Mounjaro , the pharmaceutical company Eli Lilly holds a patent for both the medication and its injection delivery device. But in December 2024, the FDA announced that the tirzepatide shortage had ended. When will a generic Mounjaro be available? So, why is compounded tirzepatide even available?

Compounding 85

Compounding Dosage Compounding Pharmacies FDA 85

pharmaphorum

JUNE 10, 2025

Skip to main content Tuesday 10 June 2025 twitter linkedin facebook rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Pharmaceutical Companies 85

Pharmaceutical Companies Pharmaceutical Companies FDA 85

European Pharmaceutical Review

APRIL 26, 2024

“approval [of Pyzchiva ® (biosimilar ustekinumab)] of is a crucial step towards offering European patients an additional safe and effective treatment option” Pharmaceutical company Sandoz has announced that the European Commission (EC) has granted marketing authorisation for Pyzchiva ® (biosimilar ustekinumab ).

Packaging 98

Packaging Pharmaceutical Companies Pharmaceutical Companies FDA 98

pharmaphorum

AUGUST 7, 2024

Cheryl Barton Mike.Hammerton Wed, 07/08/2024 - 10:51 Cheryl Barton Dr Cheryl L Barton is an independent consultant with over 20 years' research and business analysis experience.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Communication 52

European Pharmaceutical Review

MAY 28, 2025

[Currently,] an effective non-opioid treatment for chronic pain remains elusive” Mark Mintun , Eli Lilly group Vice President, Neuroscience Research and Development, explained that an effective non-opioid treatment for chronic pain remains elusive” As such, the pharmaceutical company is eager to continue development of the Na V 1.8

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Dosage 52

European Pharmaceutical Review

AUGUST 9, 2023

The pharmaceutical company announced that it plans to submit to global health authorities in 2024. In post-hoc analyses from pivotal Phase III registration studies, Xolair demonstrated a 78 percent improvement in quality of life for patients. There were 470 participants in the REMIX-1 study.

Immunization 94

Immunization Pharmaceutical Companies Pharmaceutical Companies 94

European Pharmaceutical Review

JANUARY 25, 2024

Eli Lilly and Company’s Executive Vice President of Global Quality, Johna Norton, is ending her lengthy tenure with the company this summer and retiring after 34 years of service. However, she will continue in her current role and remain as part of Eli Lilly’s Executive Committee of until 31 July 2024.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies 98